ARTICLE | Finance
With Phase III looming, Enavate leads $118M round for Moulder’s Zenas
Patient Square-backed vehicle leads round, with trial in IgG4-related diseases imminent for lead program
November 7, 2022 9:02 PM UTC
A new $118 million series B round from a syndicate led by Patient Square’s Enavate affiliate will enable Lonnie Moulder’s start-up Zenas to start Phase III testing of its mAb for IgG4-related disease and advance its global strategy for its immunology pipeline.
The round will allow Zenas BioPharma LLC to begin a pivotal study by year-end of obexelimab, a bifunctional molecule targeting CD19 and FCGR2B to which the start-up obtained global rights from Xencor Inc. (NASDAQ:XNCR) in November 2021...